Please login to the form below

Not currently logged in
Email:
Password:

Former Boehringer diabetes marketing VP joins Gelesis

Dr David Pass takes up the chief operating officer position

Gelesis Dr David PassGelesis, a biotech focused on the development of products to improve glycaemic control, has appointed Dr David Pass as its chief operating officer.

Dr Pass brings over 20 years of commercial expertise in the diabetes and metabolics areas among others to Gelesis, and takes on responsibility for all business development and product commercialisation, including the firm's lead candidate, Gelesis100.

Most recently, Dr Pass served as Boehringer Ingelheim's vice president of marketing for its diabetes portfolio, and led the pharma firm's alliance with Lilly & Co on mid- and late-stage diabetes compound development.

He has previously worked at Gilead Sciences as senior director of cardiovascular strategic marketing, at Johnson & Johnson as vice president of marketing for pain and institutional therapies, and as director of marketing at Bristol-Myers Squibb.

Yishai Zohar, chief executive officer of Gelesis, said: “We are excited to have David onboard as we prepare for the potential launch of our first product, Gelesis100.

“David brings invaluable commercial, strategic and business development experience across a broad range of therapeutic areas and has a proven track record of building successful franchises.”

8th September 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics